Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors
At American Association for Cancer Research Annual Meeting 2022New Orleans, April 8 – 13 NANTES,…